THERAPY DOSSIER · th-a563ba329f95

Human umbilical cord mesenchymal stem cells combined with FTY720

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30064040 ↗2018Reported benefit

Transcriptomic analysis of lung tissues after hUC-MSCs and FTY720 treatment of lipopolysaccharide-induced acute lung injury in mouse models.

MouseEndotoxin/LPSC57BL/6Female

Model: Lipopolysaccharide-induced acute lung injury and acute respiratory distress syndrome

Mesenchymal stem cells and FTY720 each alleviated lipopolysaccharide-induced lung injury, and the combination was more effective than either alone. Transcriptomic analysis identified Gene Ontology and pathway terms and candidate target genes associated with treatment.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…